Malignant germ cell tumors of the ovary represent a distinct subset of ovarian cancers with specific treatment considerations. This protocol addresses management of dysgerminoma, immature teratoma, embryonal carcinoma, endodermal sinus (yolk sac) tumor, and nongestational choriocarcinoma.
This protocol applies to patients with a confirmed malignant germ cell tumor of the ovary. These malignant tumors include dysgerminomas, immature teratomas, embryonal tumors, and endodermal sinus (yolk sac) tumors — each with distinct biological behaviour and specific management considerations based on histologic subtype and disease stage.
Adjuvant combination chemotherapy is the cornerstone of management. BEP — a platinum-based multi-agent regimen — is the preferred option, with an alternative platinum-based combination available for select presentations where toxicity minimisation is a priority. Histologic subtype, stage, and risk stratification determine whether treatment is warranted or observation may be appropriate. Full regimen details, cycle counts, and dosing are available in the complete protocol.
The primary aim is complete clinical response, with normalization of tumor markers — including AFP, LDH, and β-hCG — serving as key indicators of response.